EUVIMEDEUVIMED entdecken
Crossref

What alters prognosis in patients who were operated for lung cancer with lymph node metastasis?

Berk Cimenoglu iD, Attila Ozdemir, Mesut Buz, Talha Dogruyol, Nedim Turan, Recep Demirhan

ANZ Journal of Surgery · 2024

DOI: 10.1111/ans.19177 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ANZ Journal of Surgery, 2024. Verfasst von Berk Cimenoglu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Thoracic Surgery Department, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Lung Neoplasms, Lymphatic Metastasis, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In this study, we investigated the clinical outcomes of patients who underwent surgery with proven lymph node metastasis.

Methods

Patients who were operated for lung cancer with pN1 or pN2 were examined in the study. The clinicopathological features and survival of the subjects were evaluated according to pN1‐pN2 status, presence of neoadjuvant treatment, Positron emission tomography and computed tomography (PET/CT) avidity on mediastinal lymph nodes and specific lymph node stations.

Results

The study examines 100 patients operated from January 2016 to December 2021. Number of cases with pN1 and pN2 disease were 45 (45%) and 55 (55%) respectively. Thirty (30%) patients received neoadjuvant treatment. The 5‐year overall survival (OS) and disease‐free survival (DFS) of the patients were computed as 42.5% and 42.4% correspondingly. The 5‐year cancer‐related survival was 55.3%. In pN2 cohort, 5‐year DFS was 67.9% in the neoadjuvant group and 15.9% in the non‐neoadjuvant group ( P = 0.042). In non‐neoadjuvant group, 5‐year DFS was 19.9% in cases with mediastinal PET/CT avidity and 56.3% in patients without mediastinal PET/CT avidity ( P = 0.018). In pN2 disease, the presence of subcarinal or paratracheal lymph node metastasis did not create a significant difference in 5‐year OS or DFS, but pulmonary ligament lymph node metastasis was found to be linked with worse survival in both 5‐year OS ( P = 0.005) and DFS ( P = 0.017).

Conclusion

The main elements related with poor prognosis were absence of neoadjuvant treatment and pulmonary ligament lymph node metastasis in pN2 disease, detecting PET/CT avid mediastinal lymph nodes in non‐neoadjuvant group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsLymphatic MetastasisPositron Emission Tomography Computed TomographyHumansMaleFemaleMiddle AgedPrognosisAgedRetrospective StudiesLymph NodesPneumonectomyNeoadjuvant TherapyNeoplasm StagingAdultLymph Node ExcisionDisease-Free SurvivalSurvival RateMediastinum

Stichwörter der Autor:innen

lung cancermediastinal lymph nodessurvival

Autor:innen und Institutionen

  • Thoracic Surgery Department, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey.
  • Medical Oncology Department, Kartal Dr. Lutfi Kirdar City Hospital, Istanbul, Turkey.

ORCID-Profile: Berk Cimenoglu

Zitieren

APA

Cimenoglu, B., Ozdemir, A., Buz, M., Dogruyol, T., Turan, N., & Demirhan, R. (2024). What alters prognosis in patients who were operated for lung cancer with lymph node metastasis?. ANZ Journal of Surgery. https://doi.org/10.1111/ans.19177

Vancouver

Cimenoglu B, Ozdemir A, Buz M, Dogruyol T, Turan N, Demirhan R. What alters prognosis in patients who were operated for lung cancer with lymph node metastasis?. ANZ Journal of Surgery. 2024. doi:10.1111/ans.19177

BibTeX
@article{Cimenoglu2024,
  author = {Cimenoglu, Berk and Ozdemir, Attila and Buz, Mesut and Dogruyol, Talha and Turan, Nedim and Demirhan, Recep},
  title = {What alters prognosis in patients who were operated for lung cancer with lymph node metastasis?},
  journal = {ANZ Journal of Surgery},
  year = {2024},
  doi = {10.1111/ans.19177}
}
Kostenlos starten →